Tags

Type your tag names separated by a space and hit enter

Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Eur J Obstet Gynecol Reprod Biol. 2013 Dec; 171(2):281-5.EJ

Abstract

OBJECTIVE

To describe trends in and patterns of antihypertensive drug use in a general obstetric population.

STUDY DESIGN

Historical cohort study. A total of 18,117 women who gave birth in a Saskatchewan hospital between January 1, 1980 and December 31, 2005 with a diagnosis of hypertensive disorders in pregnancy were identified and included in the analysis.

RESULTS

The rate of treatment with antihypertensive drugs for pregnant women with chronic hypertension rose from 19.94% in 1980-1984 to 37.63% in 2000-2005. There were similar increases in antihypertensive drug use from 1.51% to 14.47% for gestational hypertension/non-severe preeclampsia, and from 1.56% to 20.86% for severe preeclampsia/eclampsia. Methyldopa was the most frequently used drug, followed by beta-blockers, with other antihypertensive drugs accounting for about 18.43% of total uses. The use of both methyldopa and labetalol has increased in recent years while the use of other antihypertensive drugs has decreased. Other antihypertensive drugs were more commonly prescribed in earlier gestation, while methyldopa and labetalol were generally prescribed in later gestation.

CONCLUSION

The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Xie RH
Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Road, Guangzhou 510515, China; OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6; Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Canada K1H 8L6.
Guo Y
No affiliation info available
Krewski D
No affiliation info available
Mattison D
No affiliation info available
Nerenberg K
No affiliation info available
Walker MC
No affiliation info available
Wen SW
No affiliation info available

MeSH

Adrenergic beta-AntagonistsAdultAntihypertensive AgentsFemaleHumansHypertensionHypertension, Pregnancy-InducedLabetalolMethyldopaPre-EclampsiaPregnancyPregnancy Complications, CardiovascularSaskatchewan

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24139131

Citation

Xie, Ri-hua, et al. "Trends in Using Beta-blockers and Methyldopa for Hypertensive Disorders During Pregnancy in a Canadian Population." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 171, no. 2, 2013, pp. 281-5.
Xie RH, Guo Y, Krewski D, et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):281-5.
Xie, R. H., Guo, Y., Krewski, D., Mattison, D., Nerenberg, K., Walker, M. C., & Wen, S. W. (2013). Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 171(2), 281-5. https://doi.org/10.1016/j.ejogrb.2013.09.032
Xie RH, et al. Trends in Using Beta-blockers and Methyldopa for Hypertensive Disorders During Pregnancy in a Canadian Population. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):281-5. PubMed PMID: 24139131.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. AU - Xie,Ri-hua, AU - Guo,Yanfang, AU - Krewski,Daniel, AU - Mattison,Donald, AU - Nerenberg,Kara, AU - Walker,Mark C, AU - Wen,Shi Wu, Y1 - 2013/10/01/ PY - 2013/06/11/received PY - 2013/08/20/revised PY - 2013/09/24/accepted PY - 2013/10/22/entrez PY - 2013/10/22/pubmed PY - 2014/8/16/medline KW - Antihypertensive drugs KW - Cohort study KW - Pregnancy SP - 281 EP - 5 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur J Obstet Gynecol Reprod Biol VL - 171 IS - 2 N2 - OBJECTIVE: To describe trends in and patterns of antihypertensive drug use in a general obstetric population. STUDY DESIGN: Historical cohort study. A total of 18,117 women who gave birth in a Saskatchewan hospital between January 1, 1980 and December 31, 2005 with a diagnosis of hypertensive disorders in pregnancy were identified and included in the analysis. RESULTS: The rate of treatment with antihypertensive drugs for pregnant women with chronic hypertension rose from 19.94% in 1980-1984 to 37.63% in 2000-2005. There were similar increases in antihypertensive drug use from 1.51% to 14.47% for gestational hypertension/non-severe preeclampsia, and from 1.56% to 20.86% for severe preeclampsia/eclampsia. Methyldopa was the most frequently used drug, followed by beta-blockers, with other antihypertensive drugs accounting for about 18.43% of total uses. The use of both methyldopa and labetalol has increased in recent years while the use of other antihypertensive drugs has decreased. Other antihypertensive drugs were more commonly prescribed in earlier gestation, while methyldopa and labetalol were generally prescribed in later gestation. CONCLUSION: The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase. SN - 1872-7654 UR - https://www.unboundmedicine.com/medline/citation/24139131/Trends_in_using_beta_blockers_and_methyldopa_for_hypertensive_disorders_during_pregnancy_in_a_Canadian_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301-2115(13)00485-5 DB - PRIME DP - Unbound Medicine ER -